Table 1 Baseline patient clinical and medical characteristics.

From: Different diabetogenic effect of statins according to intensity and dose in patients with acute myocardial infarction: a nationwide cohort study

Variables

Moderate intensity(n = 3747)

High intensity (n = 2405)

P-value

Men

2841 (75.8%)

1966 (81.7%)

 < 0.001

Age (years)

63.7 ± 12.8

60.5 ± 12.6

 < 0.001

Systolic BP

130.3 ± 26.8

133.7 ± 26.6

 < 0.001

Diastolic BP

79.4 ± 15.9

81.6 ± 17.0

 < 0.001

BMI

23.7 ± 3.2

24.5 ± 3.3

 < 0.001

Abdominal circumstance

86.5 ± 8.6

87.5 ± 8.4

0.011

Smoking

2240 (59.8%)

1580 (65.7%)

 < 0.001

Current smoker

1564 (41.7%)

1119 (46.5%)

 < 0.001

Ex-smoker

676 (18.0%)

461 (19.2%)

0.266

Pack year

30.8 ± 23.8

27.6 ± 18.4

 < 0.001

LV ejection fraction (%)

52.5 ± 10.3

54.1 ± 9.8

 < 0.001

LVEDD

49.5 ± 6.1

49.8 ± 5.5

0.054

LVESD

34.7 ± 7.7

34.8 ± 9.8

0.959

Myocardial infarction

 ST-segment elevation

1979 (52.8%)

1284 (53.4%)

0.660

 Non-ST-segment elevation

1768 (47.2%)

1121 (46.6%)

0.660

Laboratory findings

 Total cholesterol (mg/dl)

178.2 ± 41.3

195.5 ± 44.6

 < 0.001

 Triglyceride (mg/dl)

145.7 ± 126.5

123.8 ± 109.2

 < 0.001

 HDL-cholesterol (mg/dl)

43.5 ± 11.9

44.0 ± 11.5

0.138

 LDL-cholesterol (mg/dl)

112.0 ± 38.3

127.8 ± 38.7

 < 0.001

 Glucose (mg/dl)

139.3 ± 45.9

137.6 ± 37.8

0.121

 Creatinine (mg/dl)

0.98 ± 0.93

0.96 ± 0.81

0.429

Medication

 Aspirin

3731 (99.6%)

2391 (99.4%)

0.394

 Clopidogrel

2705 (72.2%)

1443 (60.0%)

 < 0.001

 Prasugrel

409 (10.9%)

267 (11.1%)

0.819

 Ticagrelor

595 (15.9%)

680 (28.3%)

 < 0.001

 Cilostazol

373 (10.0%)

95 (4.0%)

 < 0.001

 Calcium channel blockers

210 (5.6%)

123 (5.1%)

0.407

 β blockers

3264 (87.1%)

2049 (85.2%)

0.033

 RAAS inhibitor

3157 (84.3%)

1907 (79.3%)

 < 0.001

 ACEi

2172 (58.0%)

1096 (45.6%)

 < 0.001

 ARB

1003 (26.8%)

825 (34.3%)

 < 0.001

 Atorvastatin

2135 (57.0%)

1461 (60.7%)

 < 0.001

  10 mg

822 (21.9%)

0 (0.0%)

 

  20 mg

1313 (35.0%)

0 (0.0%)

 

  40 mg

0 (0.0%)

1319 (54.8%)

 

  80 mg

0 (0.0%)

142 (5.9%)

 

 Rosuvastatin

1612 (43.0%)

944 (39.3%)

 < 0.001

  5 mg

109 (2.9%)

0 (0.0%)

 

  10 mg

1503 (41.1%)

0 (0.0%)

 

  20 mg

0 (0.0%)

944 (39.3%)

 

Procedural characteristics

 Total stent length (mm)

28.5 ± 12.4

28.4 ± 12.7

0.748

 Total stent number

1.08 ± 0.48

1.11 ± 0.49

0.018

  1. Values are mean ± SD, %, or n (%), unless noted otherwise.
  2. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BMI body mass index, BP blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, LV left ventricle, LVEDD left ventricular end diastolic diameter, LVESD left ventricular end systolic diameter, RAAS renin–angiotensin–aldosterone system.
Back to article page